oxycodone controlled release / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 58 Diseases   27 Trials   27 Trials   1449 News 


«123456789101112»
  • ||||||||||  Oxecta (oxycodone) / Assertio, Xtampza ER (oxycodone) / Collegium Pharma
    Trial completion:  Are Opioids Needed After ACL Reconstruction (clinicaltrials.gov) -  Dec 12, 2022   
    P4,  N=100, Completed, 
    Recruiting --> Completed
  • ||||||||||  oxycodone/acetaminophen / Generic mfg., oxycodone controlled release / Generic mfg.
    Journal:  Recreational marijuana laws and the misuse of prescription opioids: Evidence from National Survey on Drug Use and Health microdata. (Pubmed Central) -  Nov 7, 2022   
    However, using a two-stage procedure designed to account for staggered treatment and dynamic effects, the DD estimate of relationship between RML adoption and the likelihood of frequently misusing prescription opioids becomes positive. Although event study estimates suggest that RML adoption leads to a decrease in the frequency of prescription opioid abuse, this effect appears to dissipate after only 2 or 3 years.
  • ||||||||||  oxycodone controlled release / Generic mfg.
    Retrospective data, Journal:  Oxycodone-Naloxone Combination Hinders Opioid Consumption in Osteoarthritic Chronic Low Back Pain: A Retrospective Study with Two Years of Follow-Up. (Pubmed Central) -  Oct 28, 2022   
    In 2019, 53 patients suffering from CLBP were treated with either Oxycodone and Naloxone Prolonged Release (27 patients, OXN patients) or Oxycodone Controlled Release (26 patients, OXY patients)...From our results, we can affirm that a long-term opioid treatment with oxycodone-naloxone combination, when compared with oxycodone only, may significantly hinder the development of opioid tolerance. We were also able to confirm, in our cohort, the well known positive effect of naloxone in terms of opioid-induced bowel dysfunction incidence reduction.
  • ||||||||||  morphine/oxycodone (Q8011) / QRxPharma
    Retrospective data, Journal:  The effectiveness and safety of the rapid titration strategy of background controlled-release oxycodone hydrochloride for patients with moderate-to-severe cancer pain: A retrospective cohort study. (Pubmed Central) -  Oct 22, 2022   
    258 patients, who used regular strong opioids (morphine and CR oxycodone hydrochloride) for cancer pain across 25 three grade class hospitals in China during January 15th 2017 to April 30th 2017, were retrospectively studied...No significant difference was found among four groups for pain remission rate at 24, 72 h after treatment. Multiple comparison of NRS scores showed that the both Group B and C varied significantly with Group D (P = 0.028, P = 0.05, respectively), showing superior analgesic effect over Group D. AEs were significantly different among groups (P < 0.01), with the most frequent AEs in Group A, lowest in Group B. The rapid titration strategy of background CR oxycodone hydrochloride was effectiveness and safety in patients with moderate-to-severe cancer pain.
  • ||||||||||  oxycodone controlled release / Generic mfg.
    Canadian regulatory, Retrospective data, Journal:  On what basis did Health Canada approve OxyContin in 1996?: A retrospective analysis of regulatory data. (Pubmed Central) -  Sep 30, 2022   
    In our view, these findings underscore the need for transparency of not only of clinical trial data, but also the regulator's interpretation of such data, which is currently lacking in Canada. Furthermore, they call into question why Health Canada's role in precipitating the overdose crisis has not received greater scrutiny, including in the context of recent litigation surrounding OxyContin.
  • ||||||||||  oxycodone ER (PF614) / Ensysce Biosciences
    Trial completion:  Evaluation of Oral PF614 Relative to OxyContin (clinicaltrials.gov) -  Sep 19, 2022   
    P1b,  N=84, Completed, 
    Furthermore, they call into question why Health Canada's role in precipitating the overdose crisis has not received greater scrutiny, including in the context of recent litigation surrounding OxyContin. Recruiting --> Completed
  • ||||||||||  Xtampza ER (oxycodone) / Collegium Pharma
    Non-Medical Use of XTAMPZA ER: Motivation, Methods, and Perceptions of Tampering () -  Sep 19, 2022 - Abstract #PAINWeek2022PAINWeek_199;    
    A comparison between individual abuse-deterrent technologies could elucidate different risk profiles based on the patterns associated with the drug prescribed. Learning Objectives: List reasons for non-medical use of Xtampza ER Describe differences between non-medical use of Xtampza ER and similar drugs List methods for tampering with Xtampza ER
  • ||||||||||  cebranopadol (GRT6005) / Assertio, Grunenthal
    Cebranopadol, a Novel Potent Analgesic: Pooled Analysis of Clinical Opiate Withdrawal Scales () -  Sep 19, 2022 - Abstract #PAINWeek2022PAINWeek_166;    
    Considering its safety across a wide range of doses, cebranopadol may serve as a much-needed treatment option for patients with moderate to severe pain. Learning Objectives: Upon completion, participant will be able to describe how the development of dependence was monitored during clinical studies with cebranopadol Upon completion, participant will be able to describe the physical dependence observed in patients on cebranopadol vs patients taking comparators including placebo, tapentadol prolonged release, pregabalin, and oxycodone controlled release Upon completion, participant will be able to describe the clinical studies used to study the safety and efficacy of cebranopadol across a variety of pain types
  • ||||||||||  fentanyl citrate / Generic mfg., oxycodone controlled release / Generic mfg.
    Retrospective data, Journal:  Coverage of the opioid crisis in national network television news from 2000-2020: A content analysis. (Pubmed Central) -  Aug 4, 2022   
    Evening news segments' emphasis on personal stories, while emotionally compelling, came at the cost of thematically-framed coverage that may improve public understanding of the complexities of the epidemic. The depiction of primarily white, young adult patients with OUD revealed a need for a greater emphasis in the news on underrepresented minorities and older adults, as these populations face additional stigma and disparities in OUD treatment initiation and retention.
  • ||||||||||  oxycodone controlled release / Generic mfg.
    Journal:  ORIGINS OF THE OPIOID CRISIS AND ITS ENDURING IMPACTS. (Pubmed Central) -  Jul 15, 2022   
    Although triplicate states had higher rates of overdose deaths prior to 1996, this relationship flipped shortly after the launch and triplicate states saw substantially slower growth in overdose deaths, continuing even 20 years after OxyContin's introduction. Our results show that the introduction and marketing of OxyContin explain a substantial share of overdose deaths over the past two decades.